Literature DB >> 12959297

Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.

B Flouvat1, B Delhotal-Landes, A Cournot, F Dellatolas.   

Abstract

Plasma concentrations of lansoprazole and of its sulphone, sulphide and 5-hydroxylated metabolites were determined after oral administration of a single 30 mg dose and after 7 days of treatment with a daily 30 mg dose in 12 elderly subjects (mean age 83 years). Results after a single dose were compared with those from a historical control group of 18 young subjects (mean age 23 years). Mean values of AUC after single dose were 2668 ng ml(-1) h in the young subjects and 5216 ng ml(-1) h in the elderly (P < 0.05). Mean t 1/2z values in young and elderly subjects were 1.4 h and 2.9 h, respectively (P < 0.001). Plasma concentrations of the metabolites were similar in both groups. However, the hydroxylated metabolite of the sulphone was detected only in elderly subjects. Steady state plasma concentrations of lansoprazole were reached after 3 days of dosing with lansoprazole. The accumulation ratio was 1.31 in the elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 12959297      PMCID: PMC1364622          DOI: 10.1111/j.1365-2125.1993.tb00398.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Human gastric acid secretion following repeated doses of AG-1749.

Authors:  P Müller; H G Dammann; U Leucht; B Simon
Journal:  Aliment Pharmacol Ther       Date:  1989-04       Impact factor: 8.171

2.  Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

Authors:  H Nagaya; H Satoh; K Kubo; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

3.  Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.

Authors:  H Satoh; N Inatomi; H Nagaya; I Inada; A Nohara; N Nakamura; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

4.  Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column.

Authors:  B D Landes; G Miscoria; B Flouvat
Journal:  J Chromatogr       Date:  1992-05-20
  4 in total
  10 in total

Review 1.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Pharmacokinetic study of esomeprazole in the elderly.

Authors:  G Hasselgren; M Hassan-Alin; T Andersson; C Claar-Nilsson; K Röhss
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.

Authors:  B Delhotal-Landes; B Flouvat; J Duchier; P Molinie; F Dellatolas; M Lemaire
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

7.  Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients.

Authors:  Anne M Hanneken; Norbert Babai; Wallace B Thoreson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-27       Impact factor: 4.799

Review 8.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 10.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.